Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report

PURPOSE: Voriconazole (VCZ) is a new-generation triazol antifungal agent. CYP2C19 mutations have been reported to cause variability in VCZ pharmacokinetics, and thus lead to undesirable effects of pharmacotherapy. We observed four Caucasian patients who underwent allogenic hematopoietic stem cell tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Beata, Sienkiewicz, Donata, Urbaniak-Kujda, Jarosław, Dybko, Tomasz, Wróbel, Anna, Wiela-Hojeńska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427156/
https://www.ncbi.nlm.nih.gov/pubmed/28247033
http://dx.doi.org/10.1007/s00432-017-2357-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427156/
https://www.ncbi.nlm.nih.gov/pubmed/28247033
http://dx.doi.org/10.1007/s00432-017-2357-y

Ejemplares similares